Results 121 to 130 of about 30,146 (272)

Safety and effectiveness of the combination of 5‐azacitidine and ruxolitinib in VEXAS syndrome: A single‐centre experience

open access: yes
British Journal of Haematology, EarlyView.
Gregorio Maria Bergonzi   +13 more
wiley   +1 more source

Clinical heterogeneity in vitiligo: Identification of clinical markers based patient clusters

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Vitiligo is a chronic autoimmune disease with heterogeneous clinical presentations. This study analysed 399 patients using hierarchical clustering and identified five phenotypes based on clinical characteristics and lesion distribution. Two groups exhibited high disease activity and extensive involvement.
Laura Galissi   +8 more
wiley   +1 more source

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms [PDF]

open access: bronze, 2017
Rita Assi   +22 more
openalex   +1 more source

Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study [PDF]

open access: hybrid, 2020
Vikas Gupta   +13 more
openalex   +1 more source

Therapeutic advances in pruritus as a model of personalized medicine

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Recent advances in itch biology reveal that chronic pruritus arises from distinct neuroimmune pathways driven by cytokines, JAK, BTK and GPCRs. Targeted biologics and small molecule inhibitors such as dupilumab, nemolizumab, remibrutinib and JAK inhibitors precisely modulate these pathways, leading to a new era of personalized therapeutics in pruritus.
Kelsey Auyeung   +2 more
wiley   +1 more source

The JAK1/JAK2‐ inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release [PDF]

open access: hybrid, 2018
Maud A.W. Hermans   +6 more
openalex   +1 more source

Immune‐related toxicity profile after haematopoietic stem cell transplantation in patients with B‐ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab

open access: yes
British Journal of Haematology, EarlyView.
Olayinka Okeleji   +7 more
wiley   +1 more source

Fatal Chronic Varicella‐Zoster Viral Infection in a Young Man With Chediak–Higashi Syndrome

open access: yesPediatric Dermatology, EarlyView.
ABSTRACT Chediak–Higashi syndrome (CHS) is a rare autosomal recessive primary immunodeficiency characterized by partial oculocutaneous albinism, neurologic involvement, and a predisposition to severe infections. Patients are particularly susceptible to developing hemophagocytic lymphohistiocytosis (HLH), which significantly worsens prognosis. We report
Albane Badet   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy